JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study
JAK-Inhibitoren zur Behandlung lebensbedrohlicher und therapierefraktärer immunvermittelter Nebenwirkungen sekundär zu Immun-Checkpoint-Inhibitoren: prospektive Kohortenstudie
Journal for ImmunoTherapy of Cancer · 2025-11 · 13 (11) · e013214
DOI: 10.1136/jitc-2025-013214 ↗Auf einen Blick
Bei 24 auswertbaren Patient:innen mit schweren oder steroidrefraktären irAEs wurde unter JAK-Inhibitoren in 70,8 % eine klinische Response beobachtet. Die mediane Zeit bis zur Resolution betrug 41 Tage.
Fragestellung
Welche Wirkung haben JAK-Inhibitoren bei corticosteroidrefraktären oder lebensbedrohlichen immunvermittelten Nebenwirkungen unter Immun-Checkpoint-Inhibitoren?
Methode
Prospektive Kohortenstudie am Jewish General Hospital in Montreal; Einschluss von Patient:innen mit Grad ≥3, persistierendem Grad-2- oder lebensbedrohlichen irAEs.
Ergebnisse
29 Patient:innen erhielten JAKi; 5 starben innerhalb von 30 Tagen nach Beginn und wurden ausgeschlossen. 24 auswertbare Patient:innen; Response bei 17 (70,8 %). Myokarditis 75 %, Arthritis 100 %.
Schlussfolgerung der Autor:innen
Die Autor:innen schlussfolgern, dass JAKi eine vielversprechende, gut verträgliche Option zur Behandlung corticosteroidrefraktärer oder lebensbedrohlicher irAEs sind.
Kernaussagen
- 17 von 24 auswertbaren Patient:innen zeigten ein Ansprechen
- Median bis zur Resolution: 41 Tage
- Keine opportunistischen Infektionen oder JAKi-bedingte Hepatotoxizität; 3 Thrombosen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Kohortenstudie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 28.11.2025. Verfasst von Rami Habib und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Oncology, Jewish General Hospital, Montreal, Québec, Canada. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Janus Kinase Inhibitors, Neoplasms, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Arthritis Society of Canada.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors have revolutionized cancer treatment but can induce immune-related adverse events (irAEs), which are sometimes severe, life-threatening, or refractory to corticosteroids. Current management is largely empirical and adapted from autoimmune disease protocols. Dysregulation of the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway has been implicated in irAE pathogenesis, positioning JAK inhibitors (JAKi) as potential therapeutic agents. We hypothesized that JAKi may offer therapeutic benefit in treating corticosteroid-refractory or life-threatening irAEs.
Methods
We conducted a prospective cohort study at the Jewish General Hospital (Montreal, Canada) within the Montreal Immune-Related Adverse Events biobank, enrolling patients who developed grade ≥3 or persistent grade 2 irAEs unresponsive to corticosteroids or life-threatening irAEs requiring urgent intervention.
Results
29 patients received JAKi; 5 were excluded due to death within 30 days of initiation, leaving 24 evaluable patients (median age 69 years; 37.5% female). The majority received anti-programmed cell death protein-1 (PD-1) monotherapy (79.2%), with some receiving combination anti-cytotoxic T-lymphocyte antigen-4/PD-1 therapy (16.7%). Indications for JAKi use included myocarditis (n=8), arthritis (n=4), colitis (n=3), hepatitis (n=3), encephalitis (n=2), pneumonitis (n=2), myasthenia gravis (n=1), and sicca syndrome (n=1). JAKi were employed as second-line therapy in 7 patients, third-line in 11, and fourth-line or later in 6. Clinical response, defined as irAE resolution to grade ≤1 while on ≤10 mg prednisone equivalent without relapse for ≥30 days, was observed in 17 patients (70.8%), with median time to resolution of 41 days. Response rates were highest for myocarditis (75%) and arthritis (100%). No opportunistic infections or JAKi-related hepatotoxicity occurred; thrombotic events were identified in three individuals (10.3%).
Conclusions
These findings suggest that JAKi are a promising, well-tolerated option for managing corticosteroid-refractory or life-threatening irAEs. Further randomized studies are warranted to confirm their efficacy and safety in this setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Oncology, Jewish General Hospital, Montreal, Québec, Canada.
- McGill University Faculty of Medicine and Health Sciences, Montreal, Québec, Canada.
- Department of Medicine, Division of Rheumatology, Jewish General Hospital, Montreal, Québec, Canada.
- Lady Davis Institute for Medical Research, Montreal, Québec, Canada.
- Department of Medicine, Division of Oncology, Jewish General Hospital, Montreal, Québec, Canada khashayar.esfahani@mcgill.ca.
- Department of Oncology, St Mary's Hospital, Montreal, Québec, Canada.
Förderung
- Arthritis Society of Canada
Zitieren
APA
Habib, R., Miller, W. H., Papadopoulos, T., Del Rincon, S. V., Berger, C., Molina, M. F., Hudson, M., & Esfahani, K. (2025). JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study. Journal for ImmunoTherapy of Cancer, 13(11), e013214. https://doi.org/10.1136/jitc-2025-013214
Vancouver
Habib R, Miller WH, Papadopoulos T, Del Rincon SV, Berger C, Molina MF, et al. JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study. Journal for ImmunoTherapy of Cancer. 2025;13(11):e013214. doi:10.1136/jitc-2025-013214
BibTeX
@article{Habib2025,
author = {Habib, Rami and Miller, Wilson H and Papadopoulos, Theodore and Del Rincon, Sonia V and Berger, Claudie and Molina, Manuel Flores and Hudson, Marie and Esfahani, Khashayar},
title = {JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {11},
pages = {e013214},
doi = {10.1136/jitc-2025-013214}
}
EUVIMED